You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 295 No. 10, March 8, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  This Week in JAMA
 This Article
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

This Week in JAMA

JAMA. 2006;295:1095.

Fine Particle Exposure and Hospital Admissions

Although the adverse health effects of exposure to airborne particulate matter are well established, few studies have examined the health effects of exposure to fine-particulate matter, defined as less than 2.5 µm in aerodynamic diameter (PM2.5). Dominici and colleagues used 1999-2002 data on PM2.5 concentrations from 204 urban US counties and hospital admission data for Medicare enrollees to assess cardiovascular and respiratory health risks associated with short-term PM2.5 exposure. The authors found that short-term exposure to increasing concentrations of PM2.5 was associated with a higher risk of hospital admission for cardiovascular and respiratory diseases in this older cohort.


Figure 600061

(SEE ARTICLE)


Coffee, CYP1A2 Genotype, and MI Risk

Investigations of the association between coffee consumption and risk of myocardial infarction (MI) have yielded inconclusive results, and it is unknown whether caffeine alone is the responsible risk factor. Cornelis and colleagues assessed whether CYP1A2 genotype—which reflects rapid or slow metabolism of caffeine—modifies the association between coffee consumption and risk of nonfatal MI in a population-based case-control study. The authors found that coffee intake was associated with an increased risk of MI only among individuals with the slow caffeine metabolism allele, CYP1A2*1F.

(SEE ARTICLE)


Mass Antibiotic Distribution and Endemic Trachoma

Mass antibiotic distribution is recommended to eliminate chlamydia strains responsible for blinding trachoma, but whether a single antibiotic distribution is sufficient is not clear. Chidambaram and colleagues conducted a longitudinal cohort study, in which a single dose of oral azithromycin was offered to all residents of 8 villages in a hyperendemic region of Ethiopia. The prevalence of ocular chlamydial infection prior to treatment and at intervals for 24 months was determined in children 1 to 5 years of age. The authors found that treatment was associated with an initial significant decline in chlamydial infection, but there was a slow rise in ocular chlamydial infection during the follow-up period.

(SEE ARTICLE)


Reporting Noninferiority and Equivalence Trials

The quality of randomized clinical trials designed to assess the noninferiority or equivalence of an experimental treatment vs an active control is the subject of 2 articles in this issue of JAMA. First, Le Henanff and colleagues (SEE ARTICLE) conducted a systematic review of 162 randomized trials of noninferiority and equivalence hypotheses and found a number of deficiencies in the reporting of the trials. These included the absence of noninferiority or equivalence margins, failures to perform both intent-to-treat and per-protocol analyses, inadequacies in the reporting of results, and misleading conclusions. In a second article, Piaggio and colleagues (SEE ARTICLE) present an adapted CONSORT (Consolidated Standards of Reporting Trials) checklist for reporting noninferiority and equivalence trials, with illustrative examples and explanations for the items specified. In an editorial, Gøtzsche (SEE ARTICLE) discusses important considerations in the application, design, analysis, reporting, and interpretation of noninferiority and equivalence randomized trials.


Medical News & Perspectives

As human H5N1 avian influenza moved beyond Southeast Asia in early 2006, scientists reported advances in vaccine development and other areas.

(SEE ARTICLE)


CLINICIAN'S CORNER
Screening Colonoscopy
Clinical Crossroads

Ms G, a healthy 71-year-old woman with no family history of colon cancer, is uncertain whether to have a screening colonoscopy. Taylor discusses the epidemiology and pathophysiology of colon cancer, the effectiveness, accuracy, and adverse effects of colon cancer screening tests, and considerations when screening patients older than 65 years.

(SEE ARTICLE)


All-or-None Performance Measurement

Nolan and Berwick discuss the advantages of an all-or-none assessment strategy in achieving high-quality health care.

(SEE ARTICLE)


JAMA Peer Reviewers and Authors

Sincere thanks to the 2005 JAMA peer reviewers and authors.

(SEE ARTICLE) | (SEE ARTICLE)


Author in the Room Teleconference

Join William C. Taylor, MD, on Wednesday, April 19, 2006, from 2 to 3 PM eastern time to discuss approaches to screening for colonoscopy, reviewed in his article "A 71-Year-Old Woman Contemplating a Screening Colonoscopy," published in the March 8, 2006, issue of JAMA.

To register, go to http://www.ihi.org/AuthorintheRoom.


JAMA Patient Page

For your patients: Information about colon cancer screening.

(SEE ARTICLE)



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.